Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbralisib Monotherapy in Non-Follicular Indolent NHL
NCT03364231Phase 2Completed
- Sponsor
- TG Therapeutics, Inc.
- Start
- Nov 2017
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of umbralisib in marginal zone lymphoma (MZL), Waldenstrom macroglobulinemia (WM), sponsored by TG Therapeutics, Inc.. Started Nov 2017; status: completed.
02
Drugs
umbralisib
03
Conditions
marginal zone lymphoma (MZL)Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT03364231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03364231.